Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).
Annals of the rheumatic diseases(2023)
摘要
NCT04134728.
更多查看译文
关键词
rheumatoid arthritis, autoimmune diseases, biological therapy, cytokines, inflammation
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要